Physician profile
Rosa Calderon
NPI 1750497129
$9,454.34
in general payments reported to CMS, 2019-2025
36 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $1,481 · 2021: $1,728 · 2022: $902 · 2023: $1,351 · 2024: $1,465 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,828.67 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,476.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,422.11 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Abbvie INC. | $491.79 | 2020-2025 | Linzess, Viberzi, Creon |
| Kowa Pharmaceuticals America, INC. | $426.51 | 2021-2025 | Zoryve, Seglentis |
| Ironwood Pharmaceuticals, INC | $319.76 | 2019-2024 | Linzess |
| Lilly USA, LLC | $285.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $181.13 | 2019-2021 | |
| Stryker Corporation | $166.54 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mannkind Corporation | $152.25 | 2019-2021 | |
| Novo Nordisk INC | $150.43 | 2019-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $144.87 | 2020 | |
| Daiichi Sankyo INC. | $138.48 | 2019-2025 | Datroway |
| Philips North America LLC | $136.85 | 2019-2025 | Vest Therapy Und |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Qiagen, LLC | $97.75 | 2020 | |
| Novartis Pharmaceuticals Corporation | $91.91 | 2024 | |
| Amarin Pharma, INC. | $82.23 | 2020-2021 | |
| Ardelyx, INC. | $63.83 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $54.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.39 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $48.03 | 2023-2024 | Austedo Xr |
| Horizon Therapeutics Plc | $40.15 | 2020-2022 | |
| Bardy Diagnostics, INC. | $36.98 | 2019 | |
| Dexcom, INC. | $33.66 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $33.04 | 2019-2024 | Xarelto |
| Aimmune Therapeutics, INC. | $28.18 | 2024 | |
| Shionogi INC | $25.53 | 2019 | |
| Redhill Biopharma INC. | $23.34 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.66 | 2025 | Rexulti |
| Pfizer INC. | $14.48 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.40 | 2025 | Brekiya |
| Smith+Nephew, INC. | $13.94 | 2024 | Collagenase Santyl |
| Genentech USA, INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.